SLN
NASDAQSilence Therapeutics Plc
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$13.65+7.17 (+110.56%)
2026-05-212026-08-25
News · 26 weeks36+650%
2026-03-012026-08-23
Mix2390d
- SEC Filings12(52%)
- Other3(13%)
- Offering3(13%)
- Insider2(9%)
- Earnings2(9%)
- Analyst1(4%)
Latest news
25 items- PRSilence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSsSilence Therapeutics plc, (NASDAQ:SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,944,444 ADSs. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering ex
- INSIDERSEC Form 4 filed by Large owner Griffiths Richard Ian4 - Silence Therapeutics plc (0001479615) (Issuer)
- SECSEC Form 8-K filed by Silence Therapeutics Plc8-K - Silence Therapeutics plc (0001479615) (Filer)
- SECSEC Form 424B5 filed by Silence Therapeutics Plc424B5 - Silence Therapeutics plc (0001479615) (Filer)
- PRSilence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public OfferingSilence Therapeutics plc ("Silence" or the "Company") , a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS. In addition, Silence has granted the underwriters a 30-day option to purchase up to an additional 1,944,444 ADSs at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering are expected to
- SECSEC Form S-3MEF filed by Silence Therapeutics PlcS-3MEF - Silence Therapeutics plc (0001479615) (Filer)
- SECSEC Form 424B5 filed by Silence Therapeutics Plc424B5 - Silence Therapeutics plc (0001479615) (Filer)
- PRSilence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary SharesSilence Therapeutics plc ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States. The proposed offering is a public offering registered under the U.S. Securities Act of 1933, as amended. In addition, Silence intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of ADSs proposed to be sold in the proposed offering at
- PRThe Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major MilestonesDENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) — Today's market is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT) emerging as one of the session's standout movers while biotech names AbCellera Biologics (NASDAQ:ABCL), Silence Therapeutics (NASDAQ:SLN) and NeOnc Technologies (NASDAQ:NTHI) command attention around major clinical milestones. Socket Mobile: The Breakout Stock with a New Distribution Engine Socket Mobile (NASDAQ:SCKT) is kicking off the week as one of the market's most explosive small-cap movers after announcing a strategic partnership with 3Eye Technologies, a value-added dist
- SECSilence Therapeutics Plc filed SEC Form 8-K: Regulation FD Disclosure8-K - Silence Therapeutics plc (0001479615) (Filer)
- PRSilence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class ProfileTrial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering
- SECSEC Form 10-Q filed by Silence Therapeutics Plc10-Q - Silence Therapeutics plc (0001479615) (Filer)
- SECSilence Therapeutics Plc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Silence Therapeutics plc (0001479615) (Filer)
- PRSilence Therapeutics Reports Second Quarter 2026 Financial and Business ResultsSilence Therapeutics plc, (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders Presented follow-up data from the Phase 1 SANRECO trial at the European Hematology Association (EHA) 2026 Annual Congress in June 2026 demonstrating durable efficacy results and potential best-in-class profile for divesiran in PV. The EHA 2026 poster is available here. Completed patient dosing in the Phase 2 SANRECO double-blind, placebo-co
- PRSilence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia VeraSilence Therapeutics plc, (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT. Investor Webcast & Conference Call Information Conference call link: https://register-conf.media-server.com/register/BI4a60039edc0640388f2ba0a6aab560e2 Webcast link: https://edge.media-server.com/mmc/p/q6mmpxd5 A replay of the webcast will be available on the Investors section of the Silence website at www.silence-therapeutics.com/events. About Sil
- SECAmendment: Silence Therapeutics Plc filed SEC Form 8-K: Leadership Update8-K/A - Silence Therapeutics plc (0001479615) (Filer)
- INSIDERSEC Form 4 filed by Large owner Griffiths Richard Ian4 - Silence Therapeutics plc (0001479615) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Silence TherapeuticsCantor Fitzgerald initiated coverage of Silence Therapeutics with a rating of Overweight
- SECSilence Therapeutics Plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silence Therapeutics plc (0001479615) (Filer)
- SECSEC Form 8-K filed by Silence Therapeutics Plc8-K - Silence Therapeutics plc (0001479615) (Filer)
- SECSilence Therapeutics Plc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Silence Therapeutics plc (0001479615) (Filer)
- PRSilence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia VeraNew analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy use persisting after final dose Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in August 2026 Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematolo
- SECSEC Form EFFECT filed by Silence Therapeutics PlcEFFECT - Silence Therapeutics plc (0001479615) (Filer)
- SECSEC Form 424B5 filed by Silence Therapeutics Plc424B5 - Silence Therapeutics plc (0001479615) (Filer)
- PRSilence Therapeutics to Participate in Jefferies Global Healthcare ConferenceSilence Therapeutics plc (NASDAQ:SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET. A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered me
SLN FAQ
6 questionsWhat does Silence Therapeutics Plc do?
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is...Where does SLN stock trade?
Silence Therapeutics Plc (SLN) is listed on NASDAQ.What sector and industry is SLN in?
Silence Therapeutics Plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about SLN?
Silence Therapeutics Plc has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-06-24.What companies are similar to SLN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SLN side-by-side with any of them on Quantisnow.How can I track SLN on Quantisnow?
Quantisnow aggregates Silence Therapeutics Plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLN to receive live email and push alerts on every new disclosure.